StockData

Ultragenyx Pharmaceutical vs Telix Pharmaceuticals

RARE and TLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How RARE and TLX compare

Telix Pharmaceuticals grew revenue faster over the last twelve months (55.6% versus 17.5% for Ultragenyx Pharmaceutical).

Telix Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −0.89% compared with −81.7% at Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical scores higher on the StockData Score (9 against 3 for Telix Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricRARETLX
Size and price
Market cap$1.6B–
Share price$16.70$8.86
Change, 1 year−49.5%−5.2%
Change, 5 years−78.2%–
Beta (5Y)2.121.10
Employees1,3711,120
StockData Score
Total score9 (better)3
Valuation score1 (better)0
Growth score2 (better)1
Performance score11
Health score5 (better)1
Dividend score00
Valuation
P/S2.3×–
FCF yield−29.7%–
Growth
Revenue growth (TTM)17.5%55.6% (better)
Revenue growth, 5Y average19.9%–
Net income growth (TTM)–−121%
EPS growth (TTM)–−122%
Profitability
Gross margin–53.1%
Operating margin−73.6%3.7% (better)
Net margin−81.7%−0.89% (better)
FCF margin−68.2%−5.3% (better)
Financial health
Net debt / EBITDA–5.17
Interest coverage–0.7×
Current ratio1.732.01 (better)
Altman Z-score−5.26–
Piotroski F-score5 (better)2
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions108%0.94%
Held by insiders4.0%8.3%
Insider net buying, 12 months−$3.8M$1.0M (better)
Short interest, % of float25.0%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.